Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $645.5MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Baker Bros. Advisors Lp | Former 10% owner | Jul 14 '26 | Sale | $102.50 | 3,100,000 | $317,750,000 | 442,940 | Jul 16 05:42 PM |
| 667, L.p. | Former Affiliate | Jul 14 '26 | Proposed Sale | $102.50 | 261,368 | $26,790,220 | — | Jul 14 09:45 PM |
| Baker Brothers Life Sciences, | Former Affiliate | Jul 14 '26 | Proposed Sale | $102.50 | 2,838,632 | $290,959,780 | — | Jul 14 09:43 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.